SUMMARY

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• Please refer to the local labeling for relevant information on dosage and administration for STELARA.
• The phase 3 clinical trial program of STELARA in the treatment of ulcerative colitis (UC) did not evaluate the use of subcutaneous (SC) formulation as induction therapy.¹

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 21 August 2024.

REFERENCES

1. Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2019;381(13):1201-1214.